drugset / Trial / NCT00110708

Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism

NCT00110708 ↗

Phase 2 Unknown 120 enrolled PediaMed Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if human immunoglobulin given by mouth twice a day is effective in treating the persistent gastrointestinal (GI) problems such as diarrhea, constipation, abdominal pain, and bloating, in children with autism.

Timeline

Start
2005-04
Primary completion
—
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Oralgam Protein / enzyme biologic 140 mg Oral
Subject Oralgam Protein / enzyme biologic 420 mg Oral
Subject Oralgam Protein / enzyme biologic 840 mg Oral